Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM PHOSPHATES IN 0 9 SODIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM PHOSPHATES IN 0 9 SODIUM CHLORIDE.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Phosphate supplementation to correct hypophosphatemia; acts as a buffer and is essential for cellular energy metabolism (ATP), bone mineralization, and acid-base balance.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
IV: 2.5-5 mmol phosphate/kg body weight over 24 hours; typical dose 10-30 mmol phosphate over 4-6 hours; do not exceed 60 mmol phosphate/day.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Phosphate: 3-4 hours in healthy adults; prolonged with renal impairment. Potassium: short distribution half-life (~1-1.5 hours); no true terminal half-life due to tight regulation.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: >90% of phosphate is reabsorbed or excreted by the kidneys; potassium is primarily excreted renally. Fecal elimination accounts for <10% of total phosphate loss.
Category C
Category A/B
Electrolyte
Electrolyte